Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03369730 · ClinicalTrials.gov registry record
Reducing the Duration of Untreated Psychosis in the United States
A clinical trial, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- 94
- Enrollment target
NCT03369730 is a clinical trial that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 94 participants.
The verdict
NCT03369730 has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- 94 participants
- Enrollment target
Study Summary
The goal of this project is to investigate whether a systematic screening approach for individuals with first episode psychosis (FEP) can substantially reduce Duration of Untreated Psychosis (DUP). The study team will evaluate the feasibility of screening a consecutive help-seeking population entering mental health services in order to facilitate early identification of FEP cases, rapid referral to specialty care and engagement in treatment.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2018-02-19 |
| Est. Completion | 2021-09-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03369730
The ClinicalTrials.gov registry entry for NCT03369730 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 94 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT03369730 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03369730 about?
NCT03369730 is a clinical study titled "Reducing the Duration of Untreated Psychosis in the United States". The goal of this project is to investigate whether a systematic screening approach for individuals with first episode psychosis (FEP) can substantially reduce Duration of Untreated Psychosis (DUP). The study team will evaluate the feasibility of screening a consecutive help-seeking population enteri...
What is the current status of trial NCT03369730?
This trial is currently completed. The enrollment target is 94 participants. The study started on 2018-02-19. Estimated completion is 2021-09-15.
Who is sponsoring clinical trial NCT03369730?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.